BackPharming Group N.V. Overview
Pharming Group N.V. - ADR

Pharming Group N.V. PEG Ratio

Pharming Group N.V. (PHAR) has a PEG ratio of -110.51, below the Healthcare sector average of 3.22.

Get informed when a big investor buys or sells

+ Follow

PEG Ratio

-110.51

PEG Ratio

-110.51

The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.

PEG Ratio (Comparison Companies)

Loading

PEG Ratio History

Loading

PEG Ratio Comparison

Loading

Pharming Group N.V. (PHAR) FAQ

Pharming Group N.V. (PHAR) currently reports a PEG ratio of -110.51. That is below the Healthcare sector average of 3.22. Use the charts on this page to explore Pharming Group N.V.'s PEG ratio history and peer comparisons.

Pharming Group N.V.'s PEG ratio of -110.51 is lower than the Healthcare sector average of 3.22. That is roughly 3529.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The PEG ratio is a valuation multiple that relates Pharming Group N.V.'s market price to a fundamental measure such as earnings, sales, or book value. At -110.51, PHAR can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current PEG ratio of -110.51, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 3.22. From there, open related valuation or income-statement pages for Pharming Group N.V., and consider following PHAR for alerts when major investors trade the stock.

Pharming Group N.V. is classified in the Healthcare sector. On PEG ratio, it currently shows -110.51 versus a sector average near 3.22. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PHAR with unrelated industries.